Sign In
Buy RCEL
$4.16
-0.0300 (-0.716%)
At Close: Jun 03, 2026
Avita Medical, Inc. Signs Agreement with Premier, Inc. to Supply the RECELL® System to Hospitals and Health Systems Across the U.S.
09:01pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
Agreement ensures timely access to the RECELL System for the approximately 4,440 U.S. hospitals and health systems in Premier’s network Agreement ensures timely access to the RECELL System for the a
AVITA Medical Reports Quarter Ending December 31, 2021, and Transition Period July 1, 2021, to December 31, 2021, Financial Results
09:01pm, Monday, 28'th Feb 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 28, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (the “Company”), a regenerative medicine company that is developing and c
AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
08:55pm, Monday, 28'th Feb 2022
AVITA Medical Inc. (RCEL) CEO Mike Perry on Q4 2021 Results - Earnings Call Transcript
The RECELL® System Receives PMDA Approval in Japan and AVITA Medical will Commercialize in Partnership with COSMOTEC, an M3 Group Company
09:29pm, Wednesday, 23'rd Feb 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a te
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
09:01pm, Wednesday, 23'rd Feb 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a te
AVITA Medical to Present at the Cowen 42nd Annual Health Care Conference
04:01pm, Wednesday, 23'rd Feb 2022
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 23, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tech
AVITA Medical Announces FDA Approval of New RECELL® System with Improved Ease of Use
09:01pm, Thursday, 17'th Feb 2022 GlobeNewswire Inc.
System enhanced in response to clinician workflow and usability feedback; new system simplifies process
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
09:01pm, Tuesday, 15'th Feb 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a te
AVITA Medical to Announce Transition Period July 1, 2021 to December 31, 2021 Financial Results
04:01pm, Tuesday, 15'th Feb 2022
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a tech
AVITA Medical to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
09:01pm, Wednesday, 02'nd Feb 2022 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a te
RECELL® System Data to be Presented at 44th Annual John A. Boswick Burn & Wound Care Symposium
01:00pm, Monday, 24'th Jan 2022 GlobeNewswire Inc.
Data presentations highlight broad clinical adoption of the RECELL® System for treatment of burn wounds Data presentations highlight broad clinical adoption of the RECELL® System for treatment of bu
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Soft-Tissue Reconstruction
09:01pm, Thursday, 06'th Jan 2022 GlobeNewswire Inc.
Topline data expected in second half of 2022 Topline data expected in second half of 2022
AVITA Medical Is Interesting, But Not Just Yet
08:30am, Tuesday, 21'st Dec 2021
The company is impacted by staffing issues and the pandemic which hamper growth at the moment, but the shares are already at a 52-week low.
AVITA Medical Completes Enrollment in Pivotal Trial Evaluating the RECELL® System for Repigmentation of Stable Vitiligo
09:01pm, Wednesday, 15'th Dec 2021 GlobeNewswire Inc.
Topline data expected in second half of 2022 Topline data expected in second half of 2022
AVITA Medical, Inc. Announces Adjournment of 2021 Annual Stockholder Meeting
12:02am, Wednesday, 15'th Dec 2021 GlobeNewswire Inc.
VALENCIA, Calif. and MELBOURNE, Australia, Dec. 14, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a tec
